• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·HTSUY
Share

Hisamitsu Pharmaceutical Co., Inc. Stocks

$ 2.94Last Updated 28.07.2026

Issuer Rating

4/7
Performance

Strong

Risk

High

Recommendation

Hold

Market Cap

$ 839.03M

$ 2.94
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hisamitsu Pharmaceutical Co., Inc. is a company dedicated to the entire lifecycle of healthcare products, from initial research and development to manufacturing and global distribution of pharmaceuticals and related health solutions. It is particularly recognized for its well-known brands such as Salonpas, Salonsip, Mohrus, ByeBye-Fever, and Keplat. Beyond these, Hisamitsu's diverse portfolio encompasses prescription-only medicines, over-the-counter remedies, medical devices, nutritional supplements, and a range of topical products designed for pain relief. Established by Nihei Hisamitsu in 1847, the company maintains its corporate headquarters in Tosu, Japan.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.08.2026 16:01

Small-Cap Highlights: Cathie Wood's Investments, the Sale of Forte Biosciences, and the CBIZ Deal

01.08.2026 13:01

Apple's Short-Lived Triumph, Non-Banks Battle for Colombia, and a Dinosaur Worth Millions of Dollars

01.08.2026 04:17

Not a White Knight: How the “Savior” of “AI-Nostradamus” Makes Money by Sensing Trouble

01.08.2026 03:08

Trump Ordered New Strikes Against Iran — WSJ

01.08.2026 02:07

The Nasdaq Composite had its worst July in 20 years due to a plunge in chipmaker stocks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026